We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hematological Parameters Detect Patients with Acute VTE

By LabMedica International staff writers
Posted on 08 Oct 2019
Venous thromboembolism (VTE) encompasses deep venous thrombosis (DVT) and pulmonary embolism (PE). More...
VTE causes cardiovascular death and disability and the risk of PE‐associated mortality and morbidity extends far beyond the acute phase of the disease.

Diagnosis of VTE is often difficult, and point score criteria help to estimate the clinical likelihood of DVT and PE. Patients with a low‐to‐moderate likelihood of DVT or PE should undergo initial diagnostic evaluation with D‐dimer testing alone without obligatory imaging tests; however, the D‐dimer assay is not specific.

Internal Medicine Scientists at Ziv Medical Center (Safed, Israel) and colleagues carried out a retrospective cohort study which aimed to examine the association and correlation between VTE and various new inflammatory markers taken from medical records of 272 patients admitted with VTE and 55 patients without VTE were used as control group.

Red blood cell distribution width (RDW), mean platelet volume (MPV), neutrophil‐lymphocyte ratio (NLR), and platelet‐lymphocyte ratio (PLR) were obtained and calculated from the complete blood count which executed in the hematology unit with Beckman Coulter Gen‐S system device. NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. RDW and MPV were obtained from the results of the complete blood count (CBC).

The team reported that patients with VTE were older than controls (62 ± 18.9 versus 55.4 ± 15.1 years), respectively and female gender was predominant in the two groups. In the study group, 178/272 (66%) had DVT, 84/272 (31%) had pulmonary embolism (PE), and the rest had DVT and PE. NLR, MPV, and PLR were found to be significantly elevated in acute VTE compared to control. A ROC curve analysis of NLR and MPV for predicting acute VTE was performed, which found a cut‐off value of 5.3 for NLR, an area under curve of (0.67 [0.60‐0.75]), with a sensitivity of 69% and specificity of 57%, and a cut‐off value of 8.6 for MPV, an area under curve of (0.61 [0.53‐0.68]), with a sensitivity of 52% and specificity of 67%.

The authors concluded that the neutrophil‐lymphocyte ratio and MPV could be beneficial predictors for the early detection of potential acute VTE. The study was published on September 11, 2019, in the Journal of Clinical Laboratory Analysis.

Related Links:
Ziv Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.